Editas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.74), $0.05 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $6.77 million versus the consensus estimate of $3.85 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.